ArticleCancer research2025

Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors.

Nealia C House et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.